Login to Your Account

BMS plays the '8' ball with potential $520M Cormorant buy

By Marie Powers
News Editor

Tuesday, July 5, 2016

A fully human antibody targeting interleukin (IL)-8 that wound its way through Medarex Inc. and Genmab A/S has found a new home at BMS through the acquisition of Cormorant Pharmaceuticals AB.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription